Non-Small Cell Lung Cancer (NSCLC) Market



DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.




The Non-Small Cell Lung Cancer market report provides current treatment practices, emerging drugs, Non-Small Cell Lung Cancer market share of the individual therapies, current and forecasted Non-Small Cell Lung Cancer market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Non-Small Cell Lung Cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

About the Disease

Lung cancer mainly begins in the lungs, and it may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

There are mainly two types of lung cancer Small cell lung cancer (SCLC) and Non-small cell lung cancer (NSCLC).
NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers (IASLC, n.d.). However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC.

NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas.
In the United States, according to the data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH) out of the total lung cancer cases approximately 85% of lung cancers are NSCLC. Among those cases, squamous cell carcinoma comprised 30% cases, adenocarcinoma comprised of 40% cases, and large-cell carcinoma comprised 15% cases. Also, all other country based registries have mentioned almost same percentage for NSCLC and its major subtypes.

Diagnosis and Treatment practices
Diagnosis:
The diagnosis and staging of NSCLC are often done at the same time. The tests and procedures used in the diagnosis of NSCLC are Physical exam and history, Laboratory tests, Chest X-ray, CT scan, Sputum cytology, Thoracentesis, Fine-needle aspiration (FNA) biopsy of the Lung, Bronchoscopy, Thoracoscopy, Mediastinoscopy, Anterior Mediastinotomy, Lymph node biopsy, Molecular test, Immunohistochemistry, among others.

Some of the tests that are used to diagnose NSCLC also determine the stage of the disease such as MRI (magnetic resonance imaging), CT scan, PET scan (positron emission tomography scan), bone scan, pulmonary function test (PFT), and bone marrow aspiration and biopsy. The staging system of NSCLC is divided into various stages such as Occult (hidden) cancer, Stage 0, Stage IA1, IA2, IA3, IB, IIA, IIB, IIIA, IIIB, IIIC, IVA, and IVB.

Treatment:
There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include: Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.
Chemotherapy is used to stop the growth of cancer cells, either by killing the cells or by stopping their division. Targeted therapy is a type of treatment that uses drugs or other substances to attack specific cancer cells. These therapies usually cause less harm to normal cells than chemotherapy or radiation therapy. Monoclonal antibodies and tyrosine kinase inhibitors are the two main types of targeted therapy being used to treat advanced, metastatic, or recurrent NSCLC. Immunotherapy is a type of treatment that uses the patients’ immune system to fight cancer. Radiation therapy uses high-energy x-rays or other types of radiations to kill cancer cells or keep them from developing.

Non-Small Cell Lung Cancer Epidemiology Insights
The Non-Small Cell Lung Cancer epidemiology division provides the insights about historical and current Non-Small Cell Lung Cancer patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
·         As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.
·         As per the DelveInsight estimates, the total incident cases of NSCLC patients by histology in the 7MM were observed to be 142,566, 228,106, 57,027, and 57,027 cases of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others in the year 2017. These cases are expected to grow with a significant CAGR in the study period 2017–2030.

Emerging Therapies
The dynamics of the Non-small cell lung cancer (NSCLC) market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as AstraZeneca, Bristol-Myers-Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, Johnson & Johnson, Sanofi, GlaxoSmithKline, etc. are involved in developing drugs for Non-small cell lung cancer (NSCLC).

Non-Small Cell Lung Cancer Market Outlook

There are several treatment options available to treat this condition in the seven major markets. Typically, chemotherapy, targeted treatments, and immunotherapy—alone or in combination—are used to treat lung cancer. Besides, pharmacological treatment choices, surgery, and radiation are also frequently opted. When the patient is in the initial stages, the tumor is usually resectable. Most stage I and stage II NSCLC are treated with surgery to remove the tumor.

According to DelveInsight, Non-Small Cell Lung Cancer market in the 7MM is expected to change in the study period 2017–2030. The total therapeutic market of Non-Small Cell Lung Cancer in seven major markets was found to be USD 9,730 million in 2017 which is expected to increase during the study period (2017–2030).

Related Reports:
About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical, Bio-Tech and Medical devices companies formulate prudent business decisions for improving their performances to stay ahead of the competitors.
View full report: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-market



Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more